Ondansetron Ever Pharma (Ondansetron)

Ondansetron acts on the serotonergic pathway to control nausea and vomiting.

• Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of acute and delayed episodes.
• Radiation‑induced nausea and vomiting: prevents nausea during and after radiotherapy.
• Postoperative nausea and vomiting: helps maintain patient comfort after surgical procedures.

• Ondansetron selectively blocks serotonin (5‑HT3) receptors located on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting these receptors, it prevents the initiation of the vomiting reflex triggered by chemotherapeutic agents, radiation, or surgical stimuli.

Ondansetron may cause a range of adverse reactions.

Common Side Effects

• Headache: mild to moderate pain in the head.
• Constipation: reduced bowel movements.
• Dizziness: sensation of light‑headedness.
• Fatigue: feeling unusually tired.
• Diarrhoea: loose stools.

Serious or Rare Side Effects

• QT prolongation: potential cardiac rhythm disturbance.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities.
• Cardiac arrhythmia: irregular heartbeats.
• Stevens‑Johnson syndrome: severe skin blistering.

When using Ondansetron, consider the following precautions.

• Cardiac risk assessment: monitor QT interval in patients with known risk factors.
• Hypersensitivity: avoid in individuals with documented allergy to ondansetron or other 5‑HT3 antagonists.
• Hepatic impairment: adjust use in patients with severe liver dysfunction.
• Concomitant QT‑prolonging drugs: evaluate for additive cardiac effects.
• Pregnancy: weigh potential benefits against risks; use only if clearly needed.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron can interact with several medications.

Major Interactions (Avoid)

• Other QT‑prolonging agents (e.g., quinidine, haloperidol): increased risk of cardiac arrhythmia.
• Apomorphine: may cause severe hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely)

• Cimetidine, erythromycin, and other CYP3A4 inhibitors: may raise ondansetron plasma levels.
• Carbamazepine and other CYP3A4 inducers: may reduce ondansetron effectiveness.
• SSRIs and other serotonergic drugs: monitor for serotonin syndrome.
• Antifungals such as ketoconazole: potential increase in drug exposure.